D1ASP0RA was founded in 2016 to launch disruptive healthcare ventures. Areas of primary interest include precision medicine, regenerative medicine, and phenotypic discovery. Precision medicine tailors treatments to each patient. Advanced medicine repairs tissues damaged by disease. Phenotypic discovery identifies more effective drugs. These three areas are key to future healthcare innovation. They operate on common platform technologies including clinical genomics and manufactured cells.